Search Bar & Filters
Found 31 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of TQH3906 capsules, a once-daily oral medication, in adults aged 18 to 75 with moderate to severe plaque psoriasis. This multicenter, randomized, double-blind, placebo- and active-controlled Phase III trial compares TQH3906 with deucravacitinib and placebo. TQH3906 selectively inhibits TYK2, targeting inflammatory pathways involved in psoriasis, aiming to support its approval for treating this condition. Participants are randomly assigned in a 221 ratio to receive TQH3906 capsules 24 mg, deucravacitinib tablets 6 mg, or placebos matching each drug during a 16-week double-blind treatment phase. After this, all participants enter a 36-week open-label extension where they receive TQH3906 capsules alone. Following treatment, there is a 4-week safety follow-up period to monitor any lasting effects. Throughout the study, participants undergo regular assessments including the static Physicians Global Assessment sPGA and Psoriasis Area and Severity Index PASI to measure skin improvement up to 16 and 52 weeks. Additional evaluations focus on scalp, nail, and palmoplantar psoriasis, quality of life via the Dermatology Life Quality Index DLQI, and drug levels in the body. Safety is closely monitored during and after the treatment periods to gather comprehensive data over a year.
Actively Recruiting
Researchers are studying the safety, tolerability, and effectiveness of elecoglipron alone or combined with dapagliflozin compared to placebo in adults with type 2 diabetes mellitus T2DM who are not well controlled with lifestyle changes or other glucose-lowering medications. This Phase III trial aims to better understand how these treatments impact blood sugar control and other health measures. Participants will be randomly assigned to one of four groups elecoglipron at dose level 1 with dapagliflozin placebo, elecoglipron at dose level 2 with dapagliflozin placebo, elecoglipron at one of the studied doses combined with dapagliflozin, or matching placebos for both drugs. All medications are taken orally once daily. The study lasts 40 weeks, during which participants receive their assigned treatment and are monitored. During the study, participants will undergo regular assessments including measurements of blood sugar control HbA1c, body weight, and blood pressure from baseline to Week 40. Researchers will also track the achievement of specific blood sugar targets, weight loss percentages, and the time before needing additional diabetes medication. Safety and tolerability will be monitored throughout the treatment period. The total participation duration is approximately 40 weeks.
Actively Recruiting
Researchers are evaluating the real-world effectiveness and safety of Trastuzumab Deruxtecan T-DXd in patients with unresectable or metastatic HER2-positive or HER2-low breast cancer. This observational study focuses on patients who have previously received anti-HER2 treatments or systemic therapy and aims to understand treatment outcomes, patient characteristics, and tolerability over time. The study is sponsored by Daiichi Sankyo and collects detailed clinical and patient-reported data to provide insights into treatment patterns and safety. Participants are grouped into two cohorts those with HER2-positive breast cancer who have had one or more anti-HER2 regimens, and those with HER2-low breast cancer who have received prior systemic therapy or experienced early recurrence after adjuvant chemotherapy. All participants are starting or have recently started T-DXd treatment according to approved labeling in China. The study observes these patients from the start of treatment until study end, death, withdrawal, loss to follow-up, or closure. During the study, researchers will track time to next treatment or death, treatment duration, dosing changes, safety events, and patient-reported tolerability using questionnaires and symptom diaries. Follow-up lasts up to 36 months with ongoing data collection on clinical characteristics, treatment patterns, and safety management. This design allows for a comprehensive view of how T-DXd performs in routine clinical practice for this patient population.
Actively Recruiting
Researchers are studying the safety, tolerability, and preliminary effectiveness of a drug called HB0025 combined with chemotherapy in patients with advanced solid tumors, including non-squamous and squamous non-small cell lung cancer NSCLC and advanced endometrial cancer EC. This multicenter Phase IbII clinical trial involves dose escalation to find the maximum safe dose and dose expansion to evaluate the drugs effects. The study aims to understand how well HB0025 works with chemotherapy in these patients, particularly those who have limited treatment options or have experienced disease progression after previous therapies. The trial has two main phases Phase Ib focuses on dose escalation using a 33 method to determine the maximum tolerated dose and dose-limiting toxicities of HB0025 combined with fixed doses of chemotherapy drugs, including pemetrexed, carboplatin, and paclitaxel. After initial evaluation, patients may continue multiple cycles of combined treatment followed by maintenance therapy with HB0025 alone or combined with pemetrexed, depending on their cancer type. Phase II expands the study with multiple cohorts receiving specific doses of HB0025 combined with chemotherapy to further assess safety and preliminary efficacy, with approximately 40 subjects per cohort. Participants will undergo treatment cycles every three weeks, with evaluations including tumor assessments, laboratory tests, and monitoring for side effects. Researchers will measure outcomes such as objective response rate, disease control, overall survival, progression-free survival, and treatment-related adverse events over up to 24 months. Safety and response will be closely monitored throughout the trial, with treatment continuing until disease progression, unacceptable toxicity, withdrawal, or study completion. This study provides ongoing follow-up to evaluate the drugs impact and tolerability in advanced cancer patients.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the J-VALVE Transcatheter Aortic Valve Replacement TAVR compared to traditional Surgical Aortic Valve Replacement SAVR in patients aged 65 and older with severe aortic regurgitation Grade 3. This study aims to determine which method better manages this heart valve condition, focusing on important health outcomes such as survival and hospital readmissions. Participants will be randomly assigned to receive either the J-VALVE Transfemoral Aortic Valve system through a catheter-based procedure or a commercially available surgical biological aortic valve replacement device through open-heart surgery. Both approaches are performed by specialized heart teams, and treatment suitability is assessed carefully before enrollment. During the study, participants will be closely monitored for up to 12 months to track outcomes like mortality, stroke, and unplanned cardiac hospitalizations. Additional assessments within 30 days will include heart rhythm changes, valve function via echocardiography, quality of life questionnaires, and hospitalization length. Follow-up visits and evaluations will ensure comprehensive safety and effectiveness data collection throughout the trial period.
Actively Recruiting
Researchers are investigating the effects of amlodipine alone versus amlodipine combined with folic acid in Chinese adults aged 45 to 74 years who have H-type hypertension, specific MTHFR 677 genotypes CC or CT, elevated plasma homocysteine levels, and low serum folate. This large, multi-center, randomized, double-blind, double-dummy clinical trial aims to evaluate which treatment better reduces the risk of first ischemic stroke over five years. Participants are first screened and then enter a 2 to 4 week run-in period where they take amlodipine to assess tolerance and compliance. Afterward, eligible participants are randomized by genotype into two groups one receiving amlodipine 5mg daily with a placebo, and the other receiving amlodipine 5mg combined with 0.8mg folic acid daily with a placebo. Other blood pressure medications may be added as needed to reach target blood pressure goals. Follow-up visits occur every three months during the five-year treatment period with medication provided at each visit. Throughout the study, participants undergo interviews, clinical evaluations, and laboratory tests including genetic and blood analyses. Researchers monitor adherence, blood pressure, and cardiovascular health. The main outcome measured is the occurrence of first ischemic stroke by the end of five years. Secondary outcomes include other cardiovascular events and kidney function. Two interim analyses will be conducted during the study to assess progress and safety.
Actively Recruiting
Researchers are evaluating the effects of different amlodipine-based treatments on the risk of first ischemic stroke in Chinese adults aged 45 to 74 years with hypertension and the MTHFR 677 TT genotype. This large, multi-center, randomized, double-blind, triple-dummy controlled trial aims to compare amlodipine alone, amlodipine combined with folic acid, and amlodipine combined with folic acid plus 5-methyltetrahydrofolate over a 5-year period. The study focuses on preventing ischemic stroke as the primary outcome. Participants first undergo a screening period to confirm eligibility through interviews, clinical evaluations, and lab tests. Those who qualify enter a 2 to 4 week run-in phase with daily amlodipine to check treatment tolerance and compliance. Eligible participants are then randomly assigned to one of three daily oral treatment groups amlodipine alone, amlodipine folic acid, or amlodipine folic acid plus 5-MTHF. Additional antihypertensive medications may be added as needed to control blood pressure. Participants are followed every 3 months for drug distribution and monitoring. Throughout the study, participants will have regular clinical visits, interviews, and biological sample collections to monitor health and treatment effects. Researchers will track the incidence of first ischemic stroke and other cardiovascular and kidney outcomes over five years. Safety and treatment adherence are carefully observed, with two planned interim analyses during the trial. Total participation spans from initial screening through five years of treatment and follow-up.
Actively Recruiting
Researchers are studying a new targeted CAR-T cell therapy called RD06-05 for adults with active autoimmune diseases including systemic lupus erythematosus SLE, systemic sclerosis SSc, ANCA-associated vasculitis AAV, idiopathic inflammatory myopathies IIM, neuromyelitis optica spectrum disorder NMOSD, multiple sclerosis MS, and myasthenia gravis MG. This early-phase clinical trial aims to evaluate the safety, tolerability, how the body processes the therapy, and its effects in these patients. The study is sponsored by Nanjing Bioheng Biotech Co., Ltd. Participants will receive RD06-05 CAR-T cell injections given intravenously after a preparatory lymphodepleting treatment with fludarabine and cyclophosphamide. The study includes careful monitoring over a two-year period to observe adverse events and other outcomes related to the treatment. The trial does not use placebo or masking, and all participants receive the experimental therapy. During the study, patients will undergo regular assessments including laboratory tests for liver, kidney, blood, and coagulation function, oxygen saturation, and heart function via echocardiography. Women of childbearing potential will have pregnancy tests and must use effective contraception. Researchers will track treatment safety by recording adverse events and will evaluate clinical disease activity using established criteria specific to each autoimmune condition. Participant involvement may last at least two years to monitor long-term effects and safety.
Actively Recruiting
Researchers are evaluating depemokimab as a treatment for adults with moderate to severe chronic obstructive pulmonary disease COPD who have type 2 inflammation and uncontrolled symptoms. This Phase 3 study aims to assess the effectiveness and safety of depemokimab when added to standard care for these patients. The focus is on reducing COPD exacerbations and improving respiratory health. Participants will be randomly assigned to receive either depemokimab or a placebo along with their usual COPD treatments. Depemokimab is given as a sterile liquid formulation, and the study compares its effects against placebo over a period of up to 104 weeks. Both groups continue their optimized inhaler therapy during the trial. During the study, participants will undergo regular assessments including lung function tests, symptom questionnaires like the COPD assessment test CAT, and monitoring of exacerbations. Researchers will measure outcomes such as the rate of moderate or severe exacerbations annually and changes in respiratory symptoms. Safety and overall health are closely followed throughout the two-year treatment period.
Actively Recruiting
Stroke is one of the leading causes of death worldwide, with ischemic stroke being the most common type. Researchers are evaluating whether early administration of oral aspirin after intravenous thrombolysis improves functional outcomes for patients with acute ischemic stroke. The study aims to determine if starting aspirin treatment within 3 hours of thrombolysis can prevent neurological deterioration without increasing bleeding risks. Participants are randomly assigned to one of two groups the interventional group receives 300 mg of oral aspirin shortly after starting intravenous thrombolysis, while the control group receives a placebo. Both groups receive the best standard medical care according to current guidelines. Aspirin tablets may be chewed or given via a nasogastric tube if swallowing is difficult. The treatment is administered within 3 hours of initiating thrombolysis. During the study, participants are monitored for neurological improvements and potential complications using scales like the modified Rankin scale and NIH Stroke Scale at various time points up to 90 days after stroke. Researchers will assess functional outcomes, neurological changes, and safety measures, including the risk of intracranial hemorrhage. The total follow-up period extends to 90 days post-stroke.
1-10 of 31
1